NO20090788L - Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase - Google Patents

Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase

Info

Publication number
NO20090788L
NO20090788L NO20090788A NO20090788A NO20090788L NO 20090788 L NO20090788 L NO 20090788L NO 20090788 A NO20090788 A NO 20090788A NO 20090788 A NO20090788 A NO 20090788A NO 20090788 L NO20090788 L NO 20090788L
Authority
NO
Norway
Prior art keywords
treatment
tyrosine kinase
ret
receptor tyrosine
ret receptor
Prior art date
Application number
NO20090788A
Other languages
English (en)
Inventor
Anderson Joseph Ryan
James Sherwood
Alan Wookey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090788L publication Critical patent/NO20090788L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en metode for seleksjon av en pasient, som er en kandidat for behandling med et RET-medikament, hvorved å forutsi en økt sannsynlighet for respons på et RET-medikament. Oppfinnelsen tilveiebringer en metode for å bestemme sekvensen av RET. Metoden tilveiebringer ARMS-primere optimalisert for å bestemme sekvensen av RET. Oppfinnelsen tilveiebringer også et diagnostisk sett, omfattende en ARMS-primer.
NO20090788A 2006-09-07 2009-02-19 Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase NO20090788L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84276606P 2006-09-07 2006-09-07
PCT/GB2007/003335 WO2008029123A1 (en) 2006-09-07 2007-09-06 Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
NO20090788L true NO20090788L (no) 2009-03-13

Family

ID=38829617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090788A NO20090788L (no) 2006-09-07 2009-02-19 Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase

Country Status (12)

Country Link
US (1) US20110028498A1 (no)
EP (1) EP2064340A1 (no)
JP (1) JP2010502209A (no)
KR (1) KR20090048644A (no)
CN (1) CN101512017A (no)
AU (1) AU2007293280A1 (no)
BR (1) BRPI0716555A2 (no)
CA (1) CA2662591A1 (no)
IL (1) IL197157A0 (no)
MX (1) MX2009002471A (no)
NO (1) NO20090788L (no)
WO (1) WO2008029123A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2714937B1 (en) * 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103930571A (zh) * 2011-11-17 2014-07-16 瑞尼克斯有限公司 用于选择性分子分析的系统和方法
WO2013172961A1 (en) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA3009552A1 (en) * 2013-03-15 2014-09-18 Expression Pathology, Inc. Srm assay to indicate cancer therapy
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
JP6130755B2 (ja) * 2013-08-12 2017-05-17 ルネサスエレクトロニクス株式会社 半導体装置およびその製造方法
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2017134115A1 (en) * 2016-02-01 2017-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma
CN110446790B (zh) * 2016-11-30 2023-03-31 外来体诊断公司 使用外来体rna和无细胞dna检测血浆中的突变的方法和组合物
CN109439752B (zh) * 2018-11-16 2022-02-15 上海派森诺医学检验所有限公司 一种鉴别甲状腺髓样癌ret基因突变的特异性引物组合及其试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale

Also Published As

Publication number Publication date
BRPI0716555A2 (pt) 2013-09-24
EP2064340A1 (en) 2009-06-03
AU2007293280A1 (en) 2008-03-13
IL197157A0 (en) 2009-11-18
KR20090048644A (ko) 2009-05-14
CN101512017A (zh) 2009-08-19
WO2008029123A1 (en) 2008-03-13
US20110028498A1 (en) 2011-02-03
CA2662591A1 (en) 2008-03-13
JP2010502209A (ja) 2010-01-28
MX2009002471A (es) 2009-03-20

Similar Documents

Publication Publication Date Title
NO20090788L (no) Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase
Kario et al. 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
WO2012106514A3 (en) System and method for diagnosis and treatment
WO2008083238A3 (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
BRPI0908026B8 (pt) uso de rifaximina no tratamento de doenças do intestino
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
Verdecchia et al. Home blood pressure measurements will not replace 24-hour ambulatory blood pressure monitoring
EA201170504A1 (ru) Арильные агонисты рецептора gpr120 и их применение
WO2014015149A3 (en) Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
NO20070521L (no) Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
WO2010041149A3 (en) Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
WO2012009382A3 (en) Molecular indicators of bladder cancer prognosis and prediction of treatment response
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
Dietz et al. Aspergillus fumigatus induction of IL‐33 expression in chronic rhinosinusitis is PAR2‐dependent
WO2006046270A3 (en) Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof
NO330943B1 (no) En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav.
WO2009004914A1 (ja) フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
WO2017167942A8 (en) Method for predicting the response of melanoma patients to a medicament
WO2007085958A3 (en) Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker
WO2010148323A3 (en) Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus-related virus
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application